Recent basic and clinical research has established a link between the pathogenesis of abdominal aortic aneurysms (AAA) and matrix metalloproteinases (MMP). The discovery of the influence of MMPs on in vitro and in vivo aneurysm development has yielded promising information that may eventually decode the pathogenetic factors affecting the initiation and growth rate of AAAs. In this review, an analysis of MMPs involved in AAA disease is presented, including the data from recent research studies and planned clinical drug trails designed to retard the AAA growth by inhibiting MMP activity.
Get full access to this article
View all access options for this article.
References
1.
Yao JS: Commentary: Surgical treatment of aortic aneurysm: 50-some years later. Cardiovasc Surg11:413-415, 2003.
2.
Melton LJ III, Bickerstaff LK, Hollier LH, et al: Changing incidence of abdominal aortic aneurysms: A populationbased study. Am J Epidemiol120:379-386, 1984.
3.
Bickerstaff LK, Hollier LH, Van Peenen HJ, et al: Abdominal aortic aneurysms: The changing natural history. J Vasc Surg1:6-12, 1984.
4.
Saus J, Quinones S, Otani Y, et al: The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem263:6742-6745, 1988.
5.
Ogata Y, Enghild JJ, Nagase H: Matrix metalloproteinase-3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem267:3581-3584, 1992.
6.
Wilhelm SM, Collier IE, Marmer BL, et al: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem264:17213-17221, 1989.
7.
Moll UM, Lane B, Zucker S, et al: Localization of collagenase at the basal plasma membrane of a human pancreatic carcinoma cell line. Cancer Res50:6995-7002, 1990.
8.
Senior RM, Griffin GL, Fliszar CJ, et al: Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem266:7870-7875, 1991.
9.
Irizarry E, Newman KM, Gandhi RH, et al: Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res54:571-574, 1993.
10.
Newman KM, Jean-Claude J, Li H, et al: Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg20:814-820, 1994.
11.
Sires UI, Griffin GL, Broekelmann TJ, et al: Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J Biol Chem268:2069-2074, 1993.
12.
Birkedal-Hansen H, Moore WG, Bodden MK, et al: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med4:197-250, 1993.
13.
Tung WS, Lee JK, Thompson RW: Simultaneous analysis of 1,176 gene products in normal human aorta and abdominal aortic aneurysms using a membrane-based complementary DNA expression array. J Vasc Surg34:143-150, 2001.
14.
Patel MI, Melrose J, Ghosh P, et al: Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg24:82-92, 1996.
15.
McMillan WD, Tamarina NA, Cipollone M, et al: Size matters: The relationship between MMP-9 expression and aortic diameter. Circulation96:2228-2232, 1997.
16.
Petersen E, Wagberg F, Angquist KA: Proteolysis of the abdominal aortic aneurysm wall and the association with rupture. Eur J Vasc Endovasc Surg23:153-157, 2002.
17.
Millan WD, Pearce WH: Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg29:122-127; discussion 127-129, 1999.
18.
Lorelli DR, Jean-Claude JM, Fox CJ, et al: Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: Implications for endoleak. J Vasc Surg35:916-922, 2002.
19.
Sangiorgi G, D'Averio R, Mauriello A, et al: Plasma levels of metalloproteinases-3 and-9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation104(12 Suppl 1):I288-I295, 2001.
20.
Petrinec D, Liao S, Holmes DR, et al: Doxycycline inhibition of aneurysmal degeneration in an elastaseinduced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg23:336-346, 1996.
21.
Holmes DR, Petrinec D, Wester W, et al: Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res63:305-309, 1996.
22.
Pyo R, Lee JK, Shipley JM, et al: Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest105:1641-1649, 2000.
23.
Baxter BT, Pearce WH, Waltke EA, et al: Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (Phase II) multicenter study. J Vasc Surg36:1-12, 2002.
24.
Mosorin M, Juvonen J, Biancari F, et al: Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: A randomized, double-blind, placebocontrolled pilot study. J Vasc Surg34:606-610, 2001.
25.
Freestone T, Turner RJ, Coady A, et al: Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol15:1145-1151, 1995.
26.
Davis V, Persidskaia R, Baca-Regen L, et al: Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol18:1625-1633, 1998.
27.
Goodall S, Crowther M, Hemingway DM, et al: Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation104:304-309, 2001.
28.
Goodall S, Porter KE, Bell PR, et al: Enhanced invasive properties exhibited by smooth muscle cells are associated with elevated production of MMP-2 in patients with aortic aneurysms. Eur J Vasc Endovasc Surg24:72-80, 2002.
29.
Treharne GD, Boyle JR, Goodall S, et al: Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg86:1053-1058, 1999.
30.
Liu J, Xiong W, Baca-Regen L, et al: Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg38:1376-1383, 2003.
31.
Nagashima H, Aoka Y, Sakomura Y, et al: Matrix metalloproteinase-2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg39:447-453, 2004.
32.
Carrell TW, Burnand KG, Wells GM, et al: Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation105:477-482, 2002.
33.
Curci JA, Liao S, Huffman MD, et al: Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest102:1900-1910, 1998.
34.
Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem264:17374-17378, 1989.
35.
Knox JB, Sukhova GK, Whittemore AD, et al: Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation95:205-212, 1997.
36.
Allaire E, Forough R, Clowes M, et al: Local overexpression of TIMP-1 prevents aortic aneurysm degenerationand rupture in a rat model. J Clin Invest102:1413-1420, 1998.
37.
Nishimura K, Ikebuchi M, Kanaoka Y, et al: Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms. Int Angiol22:229-238, 2003.
38.
Eskandari MK, Vijungco JD, Flores A, et al: Enhanced abdominal aortic aneurysm in TIMP-1-deficient mice. J Surg Res123:289-293, 2005.
